WO2001074348A2 - Vasopeptidase inhibitors to treat isolated systolic hypertension - Google Patents

Vasopeptidase inhibitors to treat isolated systolic hypertension Download PDF

Info

Publication number
WO2001074348A2
WO2001074348A2 PCT/US2001/008240 US0108240W WO0174348A2 WO 2001074348 A2 WO2001074348 A2 WO 2001074348A2 US 0108240 W US0108240 W US 0108240W WO 0174348 A2 WO0174348 A2 WO 0174348A2
Authority
WO
WIPO (PCT)
Prior art keywords
group
inhibitor
oxo
vasopeptidase
vasopeptidase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/008240
Other languages
French (fr)
Other versions
WO2001074348A8 (en
Inventor
Richard A. Reeves
Robert A. Wolf
Paul I. Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to AU2001287289A priority Critical patent/AU2001287289A1/en
Priority to JP2001572093A priority patent/JP2003533440A/en
Priority to EP01964664A priority patent/EP1267855A2/en
Priority to CA002405496A priority patent/CA2405496A1/en
Publication of WO2001074348A2 publication Critical patent/WO2001074348A2/en
Publication of WO2001074348A8 publication Critical patent/WO2001074348A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • ACE angiotensin converting enzyme
  • NEP neutral endopeptidase
  • Omapatrilat is such a vasopeptidase inhibitor which is currently undergoing clinical evaluation.
  • Omapatrilat has the chemical name [4S- [4 ⁇ (R*) , 7 ⁇ , lOa ⁇ ] ] -octahydro-4- [ (2-mercapto-l-oxo ⁇ 3-phenylpropyl) amino] -5-oxo-7H- pyrido [2, 1-b] [1, 3] thiazepine-7-carboxylic acid and the structural formula
  • BMS 189,921 (gemopatrilat) is another vasopeptidase inhibitor which is currently undergoing clinical evaluation.
  • BMS 189,921 has the chemical name [S- (R*,R*) ]-hexahydro-6- [ (2-mercapto-l-oxo-3- phenylpropyl) amino] -2, 2-dimethyl-7-oxo-lH-azepine-l- acetic acid and the structural formula
  • vasopeptidase inhibitors for this use are omapatrilat or a pharmaceutically acceptable salt thereof, BMS 189,921 or a pharmaceutically ' acceptable salt thereof, or mixtures thereof. Most preferred is the use of omapatrilat.
  • vasopeptidase inhibitor or inhibitors can also be employed in combination with other types of pharmaceutically active agents such as other types of antihypertensive agents and/or agents known to be useful in reducing the frequency or severity of stroke and/or coronary disease.
  • the combination therapy can utilize a single. dose form containing the vasopeptidase inhibitor or inhibitors or a pharmaceutically acceptable salt thereof, and the other pharmaceutically active agent or agents, co-administration of separate doses of each active agent, or administration of separate doses of each active agent according to a staggered schedule.
  • systolic blood pressure is at least as important a determinant of risk for stroke and/or coronary disease as is diastolic blood pressure. While the risk for such diseases are continuously related to blood pressure, it is useful to classify hypertension into stages of severity. A widely used classification scheme appears below:
  • Stage 1 isolated systolic hypertension (systolic blood pressure 140 - 159 mm Hg with diastolic blood pressure less than 90) is the most common type of untreated hypertension.
  • the prevalence of Stage 1 isolated systolic hypertension among adults over 60 years of age is in the range of 15 to 20%.
  • 45 - 50% have stage 1 isolated systolic hypertension.
  • Elderly, untreated patients with Stage 1 isolated systolic hypertension who are free of clinically apparent cardiovascular disease have a higher prevalence of subclinical cardiovascular disease such as silent myocardial ischemia, increased left ventricular mass, and abnormal diastolic function.
  • Patients with Stage 1 isolated systolic hypertension are at increased risk for subsequent cardiovascular morbidity and mortality by 2- to 4- fold for men and women, respectively.
  • the risk factor for cardiovascular disease is even greater in diabetic patients with isolated systolic hypertension.
  • This invention is directed to the use of one or more vasopeptidase inhibitors to treat patients with isolated systolic hypertension and thereby reduce cardiovascular mobidity and mortality including fatal and non-fatal stroke, fatal and non-fatal myocardial infarction, fatal and non-fatal heart failure, and other atherosclerotic events.
  • isolated systolic hypertension may prevent the onset of atrial fibrillation, may prevent the onset of renal failure particularly in diabetic patients, and may slow or halt the progression in the stage of hypertension.
  • Various angiotensin converting enzyme inhibitors have been reported in the literature as being useful in the treatment of isolated systolic hypertension including captopril, fosinopril, enalapril, lisinopril, lisinopril plus hydrochlorothiazide, ramipril, quinapril and spirapril.
  • vasopeptidase inhibitors results in an increased lowering of systolic blood pressure as compared to the above agents which only inhibit the angiotensin converting enzyme.
  • vasopeptidase inhibitors to a greater extent then angiotension converting enzyme inhibitors are effective in lowering systolic blood pressure in both Caucasian and Black patients.
  • Angiotensin converting enzyme inhibitors including those listed above are generally less effective in lowering systolic and diastolic blood pressure in Black patients.
  • vasopeptidase inhibitors for use in treating isolated systolic hypertension according to this invention are omapatrilat or a pharmaceutically acceptable salt thereof, and BMS 189,921 or a pharmaceutically acceptable salt thereof, particularly omapatrilat.
  • the vasopeptidase inhibitor can be administered to a patient suffering from isolated systolic hypertension in an amount ranging from about 2.5 mg to about 240 mg per 24 hours, preferably from about 20 to about 100 mg per 24 hours.
  • the vasopeptidase inhibitor can be administered in one or more doses over the 24 hour period to provide the total amount of active agent within the above range. If more than one dose is administered per 24 hours, the doses may be equal or may be varied in strength.
  • the amount of active agent employed will be adjusted by the physician according to the severity of the isolated systolic hypertension and its response to the treatment. Also, if a combination of vasopeptidase inhibitors is employed, then one or both of the inhibitors may be administered in a lesser amount provided that the total combination of active agents administered is within the above range.
  • the vasopeptidase inhibitor is preferably administered orally in tablet or capsule form.
  • other methods of administration may also be utilized including sublingually, bucally, parenterally such as by subcutaneous, intraveneous, or intramuscular injection or infusion techniques, nasally such as by inhalation spray, topically such as in the form of a cream or ointment, transdermally as in the form of a patch that is applied to the skin, or rectally such as in the form of suppositories.
  • the various dosage formulations contain in addition to the vasopeptidase inhibitor conventional pharmaceutically acceptable vehicles, stabilizers, preservatives, lubricants, diluents, and other conventional ingredients.
  • the formulation may be administered for immediate release or extended release.
  • Another aspect of this invention is the treatment of isolated systolic hypertension with one or more vasopeptidase inhibitors, as described above, in combination with other types of pharmaceutically active agents.
  • vasopeptidase inhibitors as described above
  • other antihypertensive agents can be utilized in combination with the vasopeptidase inhibitors.
  • Suitable agents include diuretics such as hydrochlorothiazide, which is preferred, and bendroflumethiazide, - and/or ⁇ -adrenergic blocking agents such as propranolol hydrochloride, timolol maleate, carvedilol, metoprolol tartrate and atenolol, calcium entry blockers such as amlodipine besylate, diltiazem hydrochloride, and verapamil hydrochloride, and angiotensin II receptor antagonists such as irbesartan, losartan, valsartan, candesartan cilexetil, and eprosartan.
  • diuretics such as hydrochlorothiazide, which is preferred, and bendroflumethiazide
  • - and/or ⁇ -adrenergic blocking agents such as propranolol hydrochloride, timolol maleate, carvedilol, metop
  • Agents known to be useful in reducing the frequency or severity of stoke and/or coronary disease can also be utilized in combination with the vasopeptidase inhibitors.
  • Suitable agents include cholesterol reducing agents particularly HMG-CoA reductase inhibitors such as pravastatin sodium, simvastatin, lovastatin, atorvastatin calcium, cerivastatin sodium, and fluvastatin sodium and platelet aggregation inhibitors such as clopidogrel bisulfate, ticlopidine hydrochloride and aspirin.
  • the amount of other pharmaceutically active agents employed is that previously approved for the treatment of hypertension or the reduction of the frequency or severity, of stroke and/or coronary disease. Lesser amounts of the other pharmaceutically active agent may be employed as determined by the treating physician. Also, in the combination therapy, the amount of vasopeptidase inhibitor may be less than the amount employed in the monotherapy described above.
  • the vasopeptidase inhibitor and the other, pharmaceutically active agent or agents may be formulated as a single dosage form, may be co-administered from separate dosage forms, or may be administered from separate dosage forms according to a staggered schedule.
  • pharmaceutically acceptable salt includes alkali metal salts such as sodium and potassium, alkaline earth metal salts such as calcium and magnesium, salts derived from amino acids such as arginine, lysine, etc. and salts derived from amines such as alkylamines, e.g. t-butylamine, t-amylamine, etc., substituted alkylamines, e.g. benzylamine, dialkylamines, substituted dialkylamines, e.g. N-methyl glucamine, trialkylamines, substituted trialkylamines, and quaternary ammonium salts.
  • alkylamines e.g. t-butylamine, t-amylamine, etc.
  • substituted alkylamines e.g. benzylamine
  • dialkylamines substituted dialkylamines
  • substituted dialkylamines e.g. N-methyl glucamine
  • trialkylamines
  • Example Omapatrilat was studied in subjects with isolated systolic hypertension (seated systolic blood pressure 160 - 199 mm Hg and diastolic blood pressure less than 90 after 4 weeks of single-blind placebo lead-in) . Both a forced-dose titration (at Week 1) and an elective-dose titration (at Week 9) design were used to compare the change from baseline, relative to placebo, in trough (24 ⁇ 3 hours post dose) seated systolic blood pressure after 9 weeks and 13 weeks of once-daily oral administration of 3 dose regimens of omapatrilat.
  • Treatment regimens consisted of omapatrilat 10 mg lead-in maintained at 10 mg at week 1, electively titrated to 20 mg at week 9 for subjects with a seated systolic blood pressure greater than or equal to 140 mm Hg, or omapatrilat 20 mg lead-in maintained at 20 mg at week 1, electively titrated to 40 mg at week 9 for subjects with a seated systolic blood pressure greater than or equal to 140 mm Hg, or omapatrilat 20 mg lead-in increased to 40 mg at week 1, electively titrated to 80 mg at week 9 for subjects with a seated systolic blood pressure greater than or equal to 140 mm Hg. Placebo was mock titrated at weeks 1 and week 9.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention porte sur des inhibiteurs de vasopeptidase, notamment l'inhibiteur omapatrilat, qui sont utiles dans le traitement de l'hypertension systolique isolée. L'inhibiteur de vasopeptidase peut être utilisé en combinaison avec d'autres agents actifs d'un point de vue pharmaceutique.Disclosed are vasopeptidase inhibitors, including the inhibitor omapatrilat, which are useful in the treatment of isolated systolic hypertension. The vasopeptidase inhibitor can be used in combination with other pharmaceutically active agents.

Description

Vasopeptidase Inhibitors To Treat Isolated Systolic Hypertension
Over the last several years compounds have been reported in the patent and technical literature as possessing in a single molecule both angiotensin converting enzyme (ACE) inhibitory activity and neutral endopeptidase (EC24.11; NEP) inhibition activity. These compounds are of interest as cardiovascular agents particularly in the treatment of hypertension, congestive heart failure, and renal disease. These compounds . are also referred to as vasopeptidase, dual metalloprotease, NEP/ACE, or ACE/NEP inhibitors.
Omapatrilat is such a vasopeptidase inhibitor which is currently undergoing clinical evaluation. Omapatrilat has the chemical name [4S- [4α(R*) , 7α, lOaβ] ] -octahydro-4- [ (2-mercapto-l-oxo~3-phenylpropyl) amino] -5-oxo-7H- pyrido [2, 1-b] [1, 3] thiazepine-7-carboxylic acid and the structural formula
Figure imgf000003_0001
Omapatrilat, its preparation, and its use in treating cardiovascular diseases are disclosed by Robl in U.S. Patent 5,508,272.
BMS 189,921 (gemopatrilat) is another vasopeptidase inhibitor which is currently undergoing clinical evaluation. BMS 189,921 has the chemical name [S- (R*,R*) ]-hexahydro-6- [ (2-mercapto-l-oxo-3- phenylpropyl) amino] -2, 2-dimethyl-7-oxo-lH-azepine-l- acetic acid and the structural formula
Figure imgf000003_0002
BMS 189,921, it preparation, and its use in treating cardiovascular diseases are disclosed by Karanewsky et al. in U.S. Patent 5,552,397.
This invention is directed to the use of a vasopeptidase inhibitor to treat isolated systolic hypertension. Preferred vasopeptidase inhibitors for this use are omapatrilat or a pharmaceutically acceptable salt thereof, BMS 189,921 or a pharmaceutically ' acceptable salt thereof, or mixtures thereof. Most preferred is the use of omapatrilat.
The vasopeptidase inhibitor or inhibitors can also be employed in combination with other types of pharmaceutically active agents such as other types of antihypertensive agents and/or agents known to be useful in reducing the frequency or severity of stroke and/or coronary disease. The combination therapy can utilize a single. dose form containing the vasopeptidase inhibitor or inhibitors or a pharmaceutically acceptable salt thereof, and the other pharmaceutically active agent or agents, co-administration of separate doses of each active agent, or administration of separate doses of each active agent according to a staggered schedule.
There is compelling evidence that systolic blood pressure is at least as important a determinant of risk for stroke and/or coronary disease as is diastolic blood pressure. While the risk for such diseases are continuously related to blood pressure, it is useful to classify hypertension into stages of severity. A widely used classification scheme appears below:
Figure imgf000005_0001
Stage 1 isolated systolic hypertension (systolic blood pressure 140 - 159 mm Hg with diastolic blood pressure less than 90) is the most common type of untreated hypertension. The prevalence of Stage 1 isolated systolic hypertension among adults over 60 years of age is in the range of 15 to 20%. Of all hypertensive patients over the age of 60 years (regardless of stage) , 45 - 50% have stage 1 isolated systolic hypertension. Elderly, untreated patients with Stage 1 isolated systolic hypertension who are free of clinically apparent cardiovascular disease have a higher prevalence of subclinical cardiovascular disease such as silent myocardial ischemia, increased left ventricular mass, and abnormal diastolic function. Patients with Stage 1 isolated systolic hypertension are at increased risk for subsequent cardiovascular morbidity and mortality by 2- to 4- fold for men and women, respectively. The risk factor for cardiovascular disease is even greater in diabetic patients with isolated systolic hypertension. This invention is directed to the use of one or more vasopeptidase inhibitors to treat patients with isolated systolic hypertension and thereby reduce cardiovascular mobidity and mortality including fatal and non-fatal stroke, fatal and non-fatal myocardial infarction, fatal and non-fatal heart failure, and other atherosclerotic events. In addition, the early and effective treatment of isolated systolic hypertension may prevent the onset of atrial fibrillation, may prevent the onset of renal failure particularly in diabetic patients, and may slow or halt the progression in the stage of hypertension. Various angiotensin converting enzyme inhibitors have been reported in the literature as being useful in the treatment of isolated systolic hypertension including captopril, fosinopril, enalapril, lisinopril, lisinopril plus hydrochlorothiazide, ramipril, quinapril and spirapril. The use of vasopeptidase inhibitors according to this invention results in an increased lowering of systolic blood pressure as compared to the above agents which only inhibit the angiotensin converting enzyme. Of added importance, the vasopeptidase inhibitors to a greater extent then angiotension converting enzyme inhibitors are effective in lowering systolic blood pressure in both Caucasian and Black patients. Angiotensin converting enzyme inhibitors including those listed above are generally less effective in lowering systolic and diastolic blood pressure in Black patients. Preferred vasopeptidase inhibitors for use in treating isolated systolic hypertension according to this invention are omapatrilat or a pharmaceutically acceptable salt thereof, and BMS 189,921 or a pharmaceutically acceptable salt thereof, particularly omapatrilat. The vasopeptidase inhibitor can be administered to a patient suffering from isolated systolic hypertension in an amount ranging from about 2.5 mg to about 240 mg per 24 hours, preferably from about 20 to about 100 mg per 24 hours. The vasopeptidase inhibitor can be administered in one or more doses over the 24 hour period to provide the total amount of active agent within the above range. If more than one dose is administered per 24 hours, the doses may be equal or may be varied in strength. Of course, the amount of active agent employed will be adjusted by the physician according to the severity of the isolated systolic hypertension and its response to the treatment. Also, if a combination of vasopeptidase inhibitors is employed, then one or both of the inhibitors may be administered in a lesser amount provided that the total combination of active agents administered is within the above range.
The vasopeptidase inhibitor is preferably administered orally in tablet or capsule form. However, other methods of administration may also be utilized including sublingually, bucally, parenterally such as by subcutaneous, intraveneous, or intramuscular injection or infusion techniques, nasally such as by inhalation spray, topically such as in the form of a cream or ointment, transdermally as in the form of a patch that is applied to the skin, or rectally such as in the form of suppositories. The various dosage formulations contain in addition to the vasopeptidase inhibitor conventional pharmaceutically acceptable vehicles, stabilizers, preservatives, lubricants, diluents, and other conventional ingredients. The formulation may be administered for immediate release or extended release.
Another aspect of this invention is the treatment of isolated systolic hypertension with one or more vasopeptidase inhibitors, as described above, in combination with other types of pharmaceutically active agents. For example, other antihypertensive agents can be utilized in combination with the vasopeptidase inhibitors. Suitable agents include diuretics such as hydrochlorothiazide, which is preferred, and bendroflumethiazide, - and/or β-adrenergic blocking agents such as propranolol hydrochloride, timolol maleate, carvedilol, metoprolol tartrate and atenolol, calcium entry blockers such as amlodipine besylate, diltiazem hydrochloride, and verapamil hydrochloride, and angiotensin II receptor antagonists such as irbesartan, losartan, valsartan, candesartan cilexetil, and eprosartan. Agents known to be useful in reducing the frequency or severity of stoke and/or coronary disease can also be utilized in combination with the vasopeptidase inhibitors. Suitable agents include cholesterol reducing agents particularly HMG-CoA reductase inhibitors such as pravastatin sodium, simvastatin, lovastatin, atorvastatin calcium, cerivastatin sodium, and fluvastatin sodium and platelet aggregation inhibitors such as clopidogrel bisulfate, ticlopidine hydrochloride and aspirin.
In such combination therapies, the amount of other pharmaceutically active agents employed is that previously approved for the treatment of hypertension or the reduction of the frequency or severity, of stroke and/or coronary disease. Lesser amounts of the other pharmaceutically active agent may be employed as determined by the treating physician. Also, in the combination therapy, the amount of vasopeptidase inhibitor may be less than the amount employed in the monotherapy described above. The vasopeptidase inhibitor and the other, pharmaceutically active agent or agents may be formulated as a single dosage form, may be co-administered from separate dosage forms, or may be administered from separate dosage forms according to a staggered schedule. The term pharmaceutically acceptable salt includes alkali metal salts such as sodium and potassium, alkaline earth metal salts such as calcium and magnesium, salts derived from amino acids such as arginine, lysine, etc. and salts derived from amines such as alkylamines, e.g. t-butylamine, t-amylamine, etc., substituted alkylamines, e.g. benzylamine, dialkylamines, substituted dialkylamines, e.g. N-methyl glucamine, trialkylamines, substituted trialkylamines, and quaternary ammonium salts.
Example Omapatrilat was studied in subjects with isolated systolic hypertension (seated systolic blood pressure 160 - 199 mm Hg and diastolic blood pressure less than 90 after 4 weeks of single-blind placebo lead-in) . Both a forced-dose titration (at Week 1) and an elective-dose titration (at Week 9) design were used to compare the change from baseline, relative to placebo, in trough (24 ± 3 hours post dose) seated systolic blood pressure after 9 weeks and 13 weeks of once-daily oral administration of 3 dose regimens of omapatrilat. Treatment regimens consisted of omapatrilat 10 mg lead-in maintained at 10 mg at week 1, electively titrated to 20 mg at week 9 for subjects with a seated systolic blood pressure greater than or equal to 140 mm Hg, or omapatrilat 20 mg lead-in maintained at 20 mg at week 1, electively titrated to 40 mg at week 9 for subjects with a seated systolic blood pressure greater than or equal to 140 mm Hg, or omapatrilat 20 mg lead-in increased to 40 mg at week 1, electively titrated to 80 mg at week 9 for subjects with a seated systolic blood pressure greater than or equal to 140 mm Hg. Placebo was mock titrated at weeks 1 and week 9.
429 subjects were randomized. The mean age was 67 years, and mean baseline blood pressure was 169/82 mm Hg. The primary efficacy objective was to compare the change from baseline, relative to placebo, in trough (24 + 3 hours post dose) seated systolic blood pressure after 9 weeks of once-daily oral administration of 3 dose regimens of omapatrilat .
At week 9, all 3 omapatrilat regimens produced greater systolic and diastolic blood pressure reductions than the placebo regimen.
Figure imgf000012_0001
Additional small reductions in systolic blood pressure versus placebo were seen at Week 13.
Among those subjects with a blood pressure measurement at week 9, the percentage of normalized subjects (trough seated systolic blood pressure less than 140 mm Hg) for omapatrilat 10/10 mg was 28%; for omapatrilat 20/20 mg was 51%; and for omapatrilat 20/40 mg was 47%. Once daily omapatrilat at 80 mg produced persistent elevation in urinary atrial natriuretic peptide excretion rate at 24 hours after dosing consistent with long acting inhibition of neutral endopeptidase .
A forced-titration and elective-titration regimen of omapatrilat 10/10/20 mg, 20/20/40 mg and 20/40/80 mg given once-daily for 13 weeks to predominately elderly subjects with isolated systolic hypertension produced greater systolic blood pressure and diastolic blood pressure reductions at trough than a regimen of placebo.

Claims

We Claim:
1. The use of a vasopeptidase inhibitor alone or in combination with another antihypertensive agent and/or an agent useful in reducing the frequency or severity of stroke and/or coronary disease for the preparation of a pharmaceutical composition for treating isolated systolic hypertension.
2. Use as defined in Claim 1 wherein said vasopeptidase inhibitor is selected from the group consisting of omapatrilat or a pharmaceutically acceptable salt thereof, [S- (R*,R*) ] -hexahydro-6- [ (2- mercapto-l-oxo-3-phenylpropyl) amino] -2, 2-dimethyl-7-oxo- ' lH-azepine-1-acetic acid or a pharmaceutically acceptable salt thereof, and mixtures thereof, said other antihypertensive agent, if present, is selected from the group consisting of diuretics, α- and/or β-adrenergic blocking agents, calcium entry blockers, angiotensin II receptor antagonists, and said agent known to be useful in reducing the frequency or severity of cardiovascular events, if present, is selected from the group consisting of HMG-CoA reductase inhibitors and platelet aggregation inhibitors .
3. Use as defined in Claim 2 wherein said diuretic is hydrochlorothiazide, said α- or β-adrenergic agent is selected from the group consisting of propranolol hydrochloride, timolol maleate, metoprolol tartrate, carvedilol, and atenolol, said calcium entry blocker is selected from the group consisting of amlodipine besylate, diltiazem hydrochloride, and verapamil hydrochloride, said angiotensin II receptor antagonist is selected from the group consisting of irbesartan, losartan, valsartan, and eprosartan, said HMG-CoA reductase inhibitor is selected from the group consisting of pravastatin sodium, simvastatin, lovastatin, atorvastatin calcium, cerivastatin sodium and fluvastatin sodium, and said platelet aggregation inhibitor is selected from the group consisting of clopidogrel bisulfate, ticlopidine hydrochloride and aspirin.
4. Use as defined in Claim 1 wherein said vasopeptidase inhibitor is employed alone.
5. Use as defined in any one of Claims 1 to 4 wherein said vasopeptidase inhibitor is omapatrilat.
6. Use as defined in any one of Claims 1 to 4 wherein said vasopeptidase inhibitor is [S-(R*,R*)]~ hexahydro-6- [ (2-mercapto-l-oxo-3-phenylpropyl) amino] -2, 2- dimethyl-7-oxo-lH-azepine-l-acetic acid.
7. Use as defined in anyone of Claims 1 to 3 wherein said vasopeptidase inhibitor is employed in combination with a diuretic.
8. Use as defined in Claim 7 wherein said vasopeptidase inhibitor is omapatrilat and said diuretic is hydrochlorothiazide.
9. Use as defined in Claim 7 wherein said vasopeptidase inhibitor is [S- (R*,R*) ] -hexahydro-6- [ (2- mercapto-l-oxo-3-phenylpropyl) amino] -2,2-dimethyl-7-oxo- lH-azepine-1-acetic acid and said diuretic is hydrochlorothiazide .
PCT/US2001/008240 2000-04-03 2001-03-15 Vasopeptidase inhibitors to treat isolated systolic hypertension Ceased WO2001074348A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2001287289A AU2001287289A1 (en) 2000-04-03 2001-03-15 Vasopeptidase inhibitors to treat isolated systolic hypertensions
JP2001572093A JP2003533440A (en) 2000-04-03 2001-03-15 Vasopeptidase inhibitors to treat isolated systolic hypertension
EP01964664A EP1267855A2 (en) 2000-04-03 2001-03-15 Vasopeptidase inhibitors to treat isolated systolic hypertension
CA002405496A CA2405496A1 (en) 2000-04-03 2001-03-15 Vasopeptidase inhibitors to treat isolated systolic hypertension

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19449900P 2000-04-03 2000-04-03
US60/194,499 2000-04-03

Publications (2)

Publication Number Publication Date
WO2001074348A2 true WO2001074348A2 (en) 2001-10-11
WO2001074348A8 WO2001074348A8 (en) 2002-05-23

Family

ID=22717832

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/008240 Ceased WO2001074348A2 (en) 2000-04-03 2001-03-15 Vasopeptidase inhibitors to treat isolated systolic hypertension

Country Status (8)

Country Link
US (1) US20020004500A1 (en)
EP (1) EP1267855A2 (en)
JP (1) JP2003533440A (en)
AU (1) AU2001287289A1 (en)
CA (1) CA2405496A1 (en)
PE (1) PE20011316A1 (en)
UY (1) UY26648A1 (en)
WO (1) WO2001074348A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059345A1 (en) * 2002-01-17 2003-07-24 Novartis Ag Pharmaceutical compositions comprising valsartan and nep inhibitors
WO2007045663A3 (en) * 2005-10-19 2008-03-27 Novartis Ag Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
US8877938B2 (en) 2005-11-09 2014-11-04 Novartis Pharmaceuticals Corporation Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
WO2019108653A1 (en) 2017-11-28 2019-06-06 Anavex Life Sciences Corp. Sigma-1 receptor agonist systolic blood pressure therapy

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03000388A (en) * 2000-07-13 2003-09-25 Alteon Inc Method for treating fibrotic diseases or other indications ic.
US6777443B2 (en) * 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives
US20030144269A1 (en) * 2001-12-20 2003-07-31 Block Alan J. Reducing pulse pressures and vascular stiffness in hypertensive patients by administering a vasopeptidase inhibitor
ES2282062T1 (en) 2004-06-04 2007-10-16 Teva Pharmaceutical Industries Ltd. PHARMACEUTICAL COMPOSITION CONTAINING IRBESARTAN.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No Search *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8796331B2 (en) 2002-01-17 2014-08-05 Novartis Ag Methods of treatment and pharmaceutical composition
US8101659B2 (en) 2002-01-17 2012-01-24 Novartis Ag Methods of treatment and pharmaceutical composition
RU2334513C2 (en) * 2002-01-17 2008-09-27 Новартис Аг Pharmaceutical compositions including valsartan and inhibitors of neutral endopeptitas (nep)
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
KR100984939B1 (en) * 2002-01-17 2010-10-01 노파르티스 아게 Pharmaceutical composition comprising valsartan and NEP inhibitor
JP2005514441A (en) * 2002-01-17 2005-05-19 ノバルティス アクチエンゲゼルシャフト Pharmaceutical composition comprising valsartan and NEP inhibitor
JP4820056B2 (en) * 2002-01-17 2011-11-24 ノバルティス アーゲー Pharmaceutical composition comprising valsartan and NEP inhibitor
WO2003059345A1 (en) * 2002-01-17 2003-07-24 Novartis Ag Pharmaceutical compositions comprising valsartan and nep inhibitors
WO2007045663A3 (en) * 2005-10-19 2008-03-27 Novartis Ag Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
US8877938B2 (en) 2005-11-09 2014-11-04 Novartis Pharmaceuticals Corporation Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
US9388134B2 (en) 2005-11-09 2016-07-12 Novartis, Ag Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
US11096918B2 (en) 2005-11-09 2021-08-24 Novartis Pharmaceuticals Corporation Amorphous solid form of compounds containing S—N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations
US11642329B2 (en) 2005-11-09 2023-05-09 Novartis Pharmaceuticals Corporation Amorphous solid form of compounds containing S—N-valeryl-N- {[2′-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations
WO2019108653A1 (en) 2017-11-28 2019-06-06 Anavex Life Sciences Corp. Sigma-1 receptor agonist systolic blood pressure therapy
EP3716968A4 (en) * 2017-11-28 2021-09-01 Anavex Life Sciences Corp. TREATMENT OF SYSTOLIC BLOOD PRESSURE BY A SIGMA -1 RECEPTOR AGONIST
US12280034B2 (en) 2017-11-28 2025-04-22 Anavex Life Sciences Corp. Sigma-1 receptor agonist systolic blood pressure therapy

Also Published As

Publication number Publication date
CA2405496A1 (en) 2001-10-11
US20020004500A1 (en) 2002-01-10
WO2001074348A8 (en) 2002-05-23
PE20011316A1 (en) 2002-01-13
EP1267855A2 (en) 2003-01-02
AU2001287289A1 (en) 2001-10-15
UY26648A1 (en) 2001-11-30
JP2003533440A (en) 2003-11-11

Similar Documents

Publication Publication Date Title
EP1467728B1 (en) Pharmaceutical compositions comprising valsartan and nep inhibitors
US8101659B2 (en) Methods of treatment and pharmaceutical composition
JP5312027B2 (en) Disease treatment
WO2007106708A2 (en) Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
WO2001074348A2 (en) Vasopeptidase inhibitors to treat isolated systolic hypertension
US20120196850A1 (en) ASSOCIATION OF A SINUS NODE If CURRENT INHIBITOR AND AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR, AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
US20100204190A1 (en) New combinations
JP2002535367A5 (en)
US7872035B2 (en) Angiotensin II antagonists
US20020013307A1 (en) Use of vasopeptidase inhibitors to treat or slow the progression of cognitive dysfunction and to treat and/or prevent dementia
Hansson Recent intervention trials in hypertension initiated in Sweden HOT, CAPPP and others
US20030144269A1 (en) Reducing pulse pressures and vascular stiffness in hypertensive patients by administering a vasopeptidase inhibitor
WO2005112940A1 (en) Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and pde v inhibitors
Ruilope 14| Vasopeptidase inhibitors
HK1106444B (en) New association of a sinus node if current inhibitor and an angiotensin-converting enzyme inhibitor, and pharmaceutical compositions containing it
AU2006202999A1 (en) Pharmaceutical compositions comprising valsartan and NEP inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

D17 Declaration under article 17(2)a
WWE Wipo information: entry into national phase

Ref document number: 2001964664

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 572093

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001287289

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2405496

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2001964664

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001964664

Country of ref document: EP